Apixaban + Warfarin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Antiphospholipid Syndrome

Conditions

Antiphospholipid Syndrome, Thrombosis

Trial Timeline

Dec 10, 2014 → Mar 1, 2022

NCT ID

NCT02295475

About Apixaban + Warfarin

Apixaban + Warfarin is a approved stage product being developed by Bristol Myers Squibb for Antiphospholipid Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02295475. Target conditions include Antiphospholipid Syndrome, Thrombosis.

What happened to similar drugs?

1 of 1 similar drugs in Antiphospholipid Syndrome were approved

Approved (1) Terminated (0) Active (0)

✅RivaroxabanBayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02942407	Approved	Completed	Dec 1, 2016	Aug 12, 2019	Atrial Fibrillation
NCT02889562	Phase 2/3	Completed	Sep 1, 2016	May 11, 2019	Coronary Artery Bypass Grafting
NCT02450682	Phase 2	Withdrawn	Feb 1, 2016	Mar 1, 2017	Atrial Fibrillation
NCT02283294	Phase 3	Completed	Apr 1, 2015	Jun 1, 2019	Transient Ischemic Attack
NCT02295475	Approved	Completed	Dec 10, 2014	Mar 1, 2022	Antiphospholipid Syndrome

Competing Products

4 competing products in Antiphospholipid Syndrome

See all competitors

Product	Company	Stage	Hype Score
RAY121	Chugai Pharmaceutical	Phase 1	36
RAY121	Chugai Pharmaceutical	Phase 1	36
Crovalimab + Placebo + VKA	Roche	Phase 2	27
Rivaroxaban	Bayer	Approved	40